MX9306572A - Nuevos compuestos cefem. - Google Patents

Nuevos compuestos cefem.

Info

Publication number
MX9306572A
MX9306572A MX9306572A MX9306572A MX9306572A MX 9306572 A MX9306572 A MX 9306572A MX 9306572 A MX9306572 A MX 9306572A MX 9306572 A MX9306572 A MX 9306572A MX 9306572 A MX9306572 A MX 9306572A
Authority
MX
Mexico
Prior art keywords
pyridylvinyl
carboxy
hydrogen
pharmaceutically acceptable
relates
Prior art date
Application number
MX9306572A
Other languages
English (en)
Inventor
Hideko Nakamura
Fumiyuki Shirai
Kazuo Sakane
Kohji Kawabata
Takeshi Terasawa
Ayako Nakamura
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929222291A external-priority patent/GB9222291D0/en
Priority claimed from GB939314495A external-priority patent/GB9314495D0/en
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of MX9306572A publication Critical patent/MX9306572A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

La presente invención se refiere a los compuestos cefem y las sales farmacéuticamente estables de éstos. Más particularmente, se relaciona con los compuestos cefem y las sales farmacéuticamente aceptables de éstos, los cuales tienen actividades antimicrobianas, con los procesos para la preparación de éstos, con la composición farmacéutica que incluye a los mismos, y con un método para el tratamiento de enfermedades infecciosas en seres humanos y animales. (ver fórmula 1). en la que R1 es amino o un amino protector, R2 es hidrógeno, un grupo protector de hidroxi, un alquilo inferior o un mono(o di o tri) haloalquilo(inferior), R3 es un carboxi o un carboxi protegido, y R4 es piridilvinilo, el cual puede tener sustituyentes adecuados, con la condición de que (i) cuando R2 es hidrógeno y R4 es 3-piridilvinilo, entonces R3 no es un carboxi, y (ii) cuando R2 es tetrahidropiranilo y R4 es 3-piridilvinilo, entonces R3 no es un bencidriloxicarbonilo, o una sal farmacéuticamente aceptable de éste.
MX9306572A 1992-10-23 1993-10-22 Nuevos compuestos cefem. MX9306572A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929222291A GB9222291D0 (en) 1992-10-23 1992-10-23 New cephem compounds
GB939314495A GB9314495D0 (en) 1993-07-12 1993-07-12 New cephem compounds

Publications (1)

Publication Number Publication Date
MX9306572A true MX9306572A (es) 1994-04-29

Family

ID=26301852

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9306572A MX9306572A (es) 1992-10-23 1993-10-22 Nuevos compuestos cefem.

Country Status (9)

Country Link
EP (1) EP0665847A1 (es)
JP (1) JPH08502513A (es)
KR (1) KR950704331A (es)
CN (1) CN1144222A (es)
CA (1) CA2147609A1 (es)
IL (1) IL107359A0 (es)
MX (1) MX9306572A (es)
TW (1) TW255894B (es)
WO (1) WO1994010177A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69737382T2 (de) 1996-11-06 2007-10-31 Basilea Pharmaceutica Ag Vinylpyrrolidinon-Cephalosporin-Derivate
TW415949B (en) * 1996-12-19 2000-12-21 Hoffmann La Roche Vinyl pyrrolidine cephalosporin derivatives with basic substituents
JP4100908B2 (ja) 1999-07-30 2008-06-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 塩基性抗生物質・無機酸塩の製造法およびシュウ酸塩中間体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4546101A (en) * 1982-09-10 1985-10-08 Fujisawa Pharmaceutical Co., Ltd. New cephem compounds useful for treating infectious diseases in human being and animals and processes for preparation thereof
GB8519606D0 (en) * 1985-08-05 1985-09-11 Fujisawa Pharmaceutical Co 3 7-d substituted-3-cephem compounds
JPH0686463B2 (ja) * 1988-07-01 1994-11-02 明治製菓株式会社 新規セフェム化合物、その製造法及び抗菌剤

Also Published As

Publication number Publication date
EP0665847A1 (en) 1995-08-09
CA2147609A1 (en) 1994-05-11
JPH08502513A (ja) 1996-03-19
TW255894B (es) 1995-09-01
KR950704331A (ko) 1995-11-17
IL107359A0 (en) 1994-01-25
WO1994010177A1 (en) 1994-05-11
CN1144222A (zh) 1997-03-05

Similar Documents

Publication Publication Date Title
ES2150489T3 (es) 1-amidinofenil-pirrolidonas, -piperidinonas, -azetinonas como inhibidores de la agregacion de plaquetas.
DE122006000051I1 (de) Ester der 5-Aminolevulins{ure als Mittel zur Photosensibillisierung in der Chemotherapie
PT98358A (pt) Processo para a preparacao de novos compostos pirazolopiridinicos
ATE321543T1 (de) Pharmazeutische zusammensetzungen mit hydroximsäurederivaten
ES2179996T3 (es) Cefalosporinas de vinil-pirrolidinona con sustituyentes basicos.
AR029151A1 (es) Una sal cuaternaria de piperidina, su uso, un proceso para su preparacion, y una composicion farmaceutica que la contiene
DK0694545T3 (da) Substituerede dibenzoxazepinforbindelser, farmaceutiske sammensætninger og anvendelsesmetoder
DE69125216D1 (de) Aminoalkanesulfonsäurederivate und pharmazeutische Zusammensetzungen davon zur Prävention oder Behandlung von Herzerkrankungen
DK0659193T3 (da) Blodpladeaggregationsinhibitorer
ES2181927T3 (es) Derivados de 1-metilcarbapenem.
MX9306680A (es) Compuestos de piridil-, quinolil- y naftilmetoxifenilo que inhiben la enzima lipoxigenasa y composiciones farmaceuticas que los contienen.
AR046874A1 (es) Nuevos metodos
PT838223E (pt) Inibidor do edema cerebral
MX9306572A (es) Nuevos compuestos cefem.
ATE161178T1 (de) Pyrazolpyridine für die behandlung der anämie
NO985202D0 (no) Anti-heliobacter pylori-preparater inneholdende 1-metylcarbapenemderivater
ES2123808T3 (es) Derivado de acilfenilglicina y agente profilactico y curativo para enfermedades causadas por una actividad acrecentada de colagenasa, que contiene dicho compuesto como ingrediente activo.
DK0556813T3 (da) Amfotere tricykliske forbindelser som antihistaminske og antiallergiske midler
DK0876144T3 (da) Terapeutiske anti-astmamidler indeholdende organiske selenforbindelser
BRPI0509533A (pt) compostos de agentes antivirais, composição farmacêutica e seus usos
DK0674645T3 (da) Cephemforbindelser med antimikrobiel virkning
GT199000080A (es) Derivados de aminoalquilbenzona substituido
PL304334A1 (en) Pharmaceutical composition of gastric protective action, including antiulceric one and method of treating diseases of gastrointestinal tract